![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/20303911-688949978-75eba3a5c24115606afd7b3a293f79dd5ecfcad4-1280x720-100x56.jpeg)
Kadimastem and Pluri Enter Cell Therapy Manufacturing Deal
PluriCDMO, Pluri's newly launched CMDO division, has been selected by Kadimastem to manufacture two novel cell therapy product candidates. Editor's note: this story was orignially published on BioPharmInternational.com. Pluri, an Israel-based …